paclitaxel has been researched along with Lassitude in 86 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (6.98) | 18.2507 |
| 2000's | 29 (33.72) | 29.6817 |
| 2010's | 45 (52.33) | 24.3611 |
| 2020's | 6 (6.98) | 2.80 |
| Authors | Studies |
|---|---|
| Beesley, VL; Campbell, R; DeFazio, A; Friedlander, ML; Grant, P; King, MT; Nagle, CM; Obermair, A; Ross, TL; Webb, PM | 1 |
| Adjei, AA; Azad, NS; Chan, WK; Cutler, D; Diamond, JR; Dy, GK; Jimeno, A; Kramer, D; Kwan, R; Lam, ET; Li, JJ; Ma, WW; Opyrchal, M; Zhi, J | 1 |
| Grant, CV; Jordan, K; Pyter, LM; Seng, MM | 1 |
| Ang, JE; Arkenau, HT; Beijnen, JH; Brunetto, AT; de Bono, JS; De Grève, J; de Jonge, MJA; Jager, A; Lolkema, MP; Marchetti, S; Mergui-Roelvink, MWJ; Schellens, JHM; Tchakov, I; van der Biessen, DA; van der Noll, R | 1 |
| Grant, CV; Jordan, KR; Pyter, LM; Sullivan, KA; Vickery, SS | 1 |
| Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A | 1 |
| Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Apte, SM; Chon, HS; Kang, S; Lee, JK; Shahzad, MM; Wenham, RM; Williams-Elson, I | 1 |
| Barzilay, R; Enzinger, A; Forsyth, AW; Hughes, KS; Lindvall, C; Lorenz, KA; Lui, D; Tulsky, JA | 1 |
| Abe, M; Chiba, T; Iino, Y; Kato, N; Mikata, R; Ogawa, Y; Ohyama, H; Suzuki, E; Tsuyuguchi, T; Yasui, S | 1 |
| Akin, S; Kas Guner, C | 1 |
| Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A | 1 |
| Jarboe, J; Saif, MW | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Ding, ZY; Guo, F; Han, YL; Liang, XF; Liu, L; Liu, ZZ; Ma, DC; Xie, XD; Yu, HY | 1 |
| Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM | 1 |
| Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H | 1 |
| Arun, B; Cohen, L; Lam, CY; Ratcliff, CG; Valero, V | 1 |
| Cao, Y; Gong, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Wu, Y; Zhang, X; Zhou, J | 1 |
| Bellon, JR; Berry, DA; Carey, LA; Cirrincione, CT; Collyar, D; Golshan, M; Hahn, OM; Hudis, CA; Kuzma, CS; Perou, CM; Pluard, TJ; Port, ER; Sikov, WM; Singh, B; Somlo, G; Tolaney, SM; Winer, EP | 1 |
| Boere, IA; de Gooyer, D; Goey, SH; Kerkhofs, LG; Kok, TC; Look, M; Onstenk, W; Ottevanger, PB; Ruit, JB; ten Bokkel Huinink, D; Valster, FA; van der Burg, ME; van der Torren, AM; van Doorn, HC; van Reisen, AG; Verweij, J | 1 |
| Cheng, J; Huang, Y; Liu, Y; Luo, R; Ouyang, M; Sun, X; Tan, W; Xiao, Y; Yu, K; Zhao, X | 1 |
| Akcakanat, A; Chen, H; Culotta, KS; Do, KA; Doyle, LA; Gonzalez-Angulo, AM; Krop, I; Kurzrock, R; Li, Y; Liu, S; Meric-Bernstam, F; Mills, GB; Moulder-Thompson, S; Piha-Paul, S; Sahin, AA; Tarco, E; Velez-Bravo, V; Winer, EP | 1 |
| Chen, S; Cui, S; Geng, C; Huang, L; Huang, T; Lei, Y; Pang, D; Shao, Z; Song, E; Tang, L; Wang, Y; Xu, B; Yang, H; Yang, W; Zhang, J; Zheng, H | 1 |
| Bertino, EM; Chatterjee, M; Mo, X; Nana-Sinkam, SP; Otterson, GA; Phillips, GS; Rahmani, M; Shilo, K; Villalona-Calero, MA; Williams, TM | 1 |
| Patel, SA | 1 |
| Bekaii-Saab, T; Kleiber, B; Lustberg, MB; Mikhail, S; Monk, P; Mortazavi, A; Ruppert, AS; Villalona-Calero, M | 1 |
| Hara, F; Hozumi, Y; Imoto, S; Matsubara, N; Mukai, H; Nishimura, R; Ohashi, Y; Park, Y; Sagara, Y; Saito, T; Shimozuma, K; Takano, T; Takashima, T; Toyama, T; Tsurutani, J; Watanabe, T | 1 |
| Adam, J; Bastien, B; Beck, JT; Chouaid, C; Debieuvre, D; Felip, E; Forget, F; Gervais, R; Halluard, C; Kazarnowicz, A; Lacoste, G; Lena, H; Limacher, JM; Losonczy, G; Madroszyk, A; Ottensmeier, C; Palanché, T; Papai, Z; Quoix, E; Szczesna, A; Tavernaro, A; Westeel, V | 1 |
| Imamura, F; Ishitobi, M; Kittaka, N; Nakayama, T; Okuno, J; Sugimoto, N; Tamaki, Y; Yagi, T; Yoshinami, T | 1 |
| Lee, JR; Oh, PJ | 1 |
| Mehta, RS; Nangia, CI; Tran, PN; Zhuang, L | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Shen, K; Wu, J; Zong, Y | 1 |
| Eggemann, H; Elling, D; Harbeck, N; Janni, W; Kaufmann, M; Kiechle, M; Kümmel, S; Loibl, S; Nekljudova, V; Sommer, H; von Minckwitz, G | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Mahoney, SL; Papadopoulos, NE | 1 |
| Camidge, DR; Chow, LQ; Cohen, RB; Diab, S; Eckhardt, SG; Fox, NL; Gore, L; Gustafson, DL; Hariharan, S; Langer, CJ; Leong, S; Miceli, R; O'Bryant, C; Padavic, K; Smith, M; von Mehren, M | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW | 1 |
| Akiya, T; Higuchi, K; Koizumi, W; Nakayama, N; Sakuyama, T; Sasaki, T; Sato, A; Sekikawa, T; Tanabe, S; Yamaguchi, K | 1 |
| Anderson, C; Gonzalez, R; Haddad, J; Hutchins, L; Jacobson, E; Kong, S; Lawson, D; O'Day, S; Weber, R; Williams, A | 1 |
| Alfaro, V; Chu, Q; Forouzesh, B; Lebedinsky, C; Mita, A; Nieto, A; Rowinsky, EK; Schwartz, G; Soto-Matos, A; Tolcher, AW | 1 |
| Aguiló, R; Alberola, V; Alonso, G; Astudillo, J; Borro, JM; Camps, C; Felip, E; González-Larriba, JL; Guijarro, R; Hermosilla, E; Isla, D; Maestre, JA; Massuti, B; Morán, T; Padilla, J; Rodríguez-Paniagua, JM; Rosell, R; Sánchez, JJ; Sánchez-Palencia, A; Torres, A | 1 |
| Bone, EA; de Jonge, M; Desar, I; Eskens, FA; Hooftman, L; Timmer-Bonte, JN; van Herpen, CM; Verweij, J | 1 |
| Battafarano, R; Birnbaum, A; Burrows, W; Dipetrillo, T; Fontaine, J; Horiba, N; Ng, T; Oldenburg, N; Perez, K; Safran, H; Suntharalingam, M | 1 |
| Ran, S; Ray, MA; Toth, LA; Trammell, RA; Verhulst, S | 1 |
| Armstrong, DK; Frasure, HE; Gil, KM; Huang, HQ; von Gruenigen, VE; Wenzel, LB | 1 |
| Bouchard, D; Brenner, A; Chandhasin, C; Elian, K; Gabrail, N; Kurzrock, R; Mita, A; Moulder, S; Sankhala, K; Sarantopoulos, J; Smith, C | 1 |
| Belinsky, SA; Dahlberg, SE; Fitzgerald, TJ; Hoang, T; Johnson, DH; Mehta, MP; Schiller, JH | 1 |
| Ancoli-Israel, S; Dimsdale, JE; Fiorentino, L; Liu, L; Mills, PJ; Natarajan, L; Parker, BA; Rissling, M; Sadler, GR | 1 |
| Berger, AM; Farr, L; Fischer, P; Geary, CR; Hertzog, M | 1 |
| Golan-Vered, Y; Pud, D | 1 |
| Bozionellou, V; Georgoulias, V; Giassas, S; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Pantazopoulos, N; Papadimitraki, E; Soultati, A; Vardakis, N | 1 |
| Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG | 1 |
| Arias-Pulido, H; Bauman, JE; Carr, LL; Cerilli, LA; Eaton, KD; Jones, DV; Lee, SJ; Martins, RG; Wallace, SG | 1 |
| Fujitani, K; Furukawa, H; Imamura, H; Imano, M; Kimura, Y; Kurokawa, Y; Matsuoka, M; Shimokawa, T; Takiuchi, H; Tokunaga, Y; Tsujinaka, T; Yano, H | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Butts, JA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH; Raefsky, EL; Steis, RG | 1 |
| Hirano, T; Kubo, H; Masaki, K; Ogura, H; Taoka, H; Terauchi, F; Yamamoto, Y | 1 |
| Arun, B; Booser, D; Bruera, E; Cleeland, CS; Fritsche, HA; Hortobagyi, GN; Ibrahim, N; Lara, J; Martinez, MM; Mendoza, TR; Pusztai, L; Reuben, JM; Rivera, E; Royce, M; Syed, A; Valero, V; Willey, JS | 1 |
| Bangert, S; Bishop, WR; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Khuri, FR; Kies, MS; Kim, ES; Kirschmeier, P; Lu, C; Meyers, ML; Munden, RF; Papadimitrakopoulou, V; Shin, DM; Statkevich, P; Tendler, C; Thall, PF; Thompson, E; Wang, XM; Zhu, Y | 1 |
| Byun, JR; Cho, SH; Chung, IJ; Kim, HJ; Kim, YK; Lee, JJ; Na, KJ; Song, SY; Yang, DH | 1 |
| Bunn, PA; Gustafson, DL; Hanna, N; Kelly, K; Long, ME; Needle, MN; Rosenberg, A; Thienelt, CD | 1 |
| Ai, B; Han, XH; He, XH; Huang, DZ; Li, B; Liu, P; Qin, Y; Shi, YK; Sun, Y; Yang, S; Zhang, CG | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Iodice, G; Rubulotta, MR; Thomas, R | 1 |
| Chen, WG; Du, LL; Lei, W; Liang, J; Ma, XZ; Xu, M | 1 |
| Daemen, J; Erdman, RA; Pedersen, SS; Serruys, PW; Sonnenschein, K; van de Sande, M; van Domburg, RT | 1 |
| Daemen, J; de Jaegere, PT; Denollet, J; Erdman, RA; Pedersen, SS; Serruys, PW; van de Sande, M; van Domburg, RT | 1 |
| Baron, AD; Burstein, HJ; Gelman, R; Hart, RD; Keshaviah, A; Lambert-Falls, R; Marcom, PK; Winer, EP | 1 |
| Jin, ML; Li, J; Li, Y; Shen, L; Zhang, XD; Zhang, XT | 1 |
| Gomella, L; Greenberg, R; Hudes, GR; Khater, C; McAleer, C; Nathan, FE; Stern, C | 1 |
| Bonjo, CA; Comis, RL; Engstrom, PF; Johnson, S; Langer, CJ; Leighton, JC; Litwin, S; McAleer, CA; O'Dwyer, PJ; Ozols, RF | 1 |
| Hande, KR; Johnson, DH; Paul, D | 1 |
| Keren-Rosenberg, S; Muggia, FM | 1 |
| Beijnen, JH; Beusenberg, FD; Doyle, E; Hearn, S; Herben, VM; Panday, VR; Richel, DJ; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van der Vange, N | 1 |
| Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B | 1 |
| Beijnen, JH; Bult, A; Huizing, MT; Lustig, V; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Bol, CJ; Palmer, PA; Sparreboom, A; van Beurden, V; van der Burg, ME; van der Gaast, A; van Zuylen, L; Verweij, J; Woestenborghs, R | 1 |
| Böhlke, I; Bokemeyer, C; Derigs, G; Hartmann, JT; Kanz, L; Mayer, F; Schröder, M; Von Pawel, J | 1 |
| Burris, HA; Erland, JB; Gray, JR; Greco, FA; Hainsworth, JD; Kalman, LA; Schreeder, MT | 1 |
| Atkinson, R; Coleman, R; Crawford, M; Cruickshank, M; Eggleton, P; Fleming, D; Graham, J; Kaye, SB; Parkin, D; Paul, J; Reed, NS; Vasey, PA | 1 |
| Baldelli, AM; Barni, S; Casaretti, R; Cascinu, S; Catalano, G; Catalano, V; Comella, G; Frontini, L; Graziano, F; Labianca, R | 1 |
| Agelidou, M; Bania, E; Georgoulias, V; Jordanoglou, J; Kakolyris, S; Kouroussis, C; Mavroudis, D; Papadakis, E; Stavrakakis, J; Tsiafaki, X; Veslemes, M; Vlachonicolis, J | 1 |
| Bunn, PA; Crowley, JJ; Gandara, DR; Kelly, K; Livingston, RB; Lovato, L; Roychowdhury, D; Taylor, SA; Zangmeister, J | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Payrits, T; Raderer, M; Scheithauer, W; Schüll, B | 1 |
3 review(s) available for paclitaxel and Lassitude
| Article | Year |
|---|---|
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2014 |
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Fatigue; Female; Humans; Leukopenia; Nanoparticles; Nausea; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Treatment Outcome | 2017 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Fatigue; Feasibility Studies; Female; Fluorouracil; Gastrointestinal Diseases; Germany; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2008 |
62 trial(s) available for paclitaxel and Lassitude
| Article | Year |
|---|---|
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Fatigue; Humans; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Treatment Outcome | 2022 |
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capsules; Carboplatin; Fatigue; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Phthalazines; Piperazines; Tablets; Thrombocytopenia | 2020 |
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Research Design; Sirolimus; Thrombocytopenia | 2017 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
[Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study].
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cytokine-Induced Killer Cells; Fatigue; Female; Humans; Immunotherapy, Adoptive; Middle Aged; Nausea; Paclitaxel; Prospective Studies; Quality of Life; Surveys and Questionnaires; Vomiting | 2013 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult | 2014 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2014 |
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Fatigue; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Middle Aged; Nausea; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2014 |
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Administration Schedule; Drug Eruptions; Fatigue; Female; Heterocyclic Compounds, 3-Ring; Humans; Hyperglycemia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Treatment Outcome | 2015 |
Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Drug Administration Schedule; Epirubicin; Fatigue; Female; Humans; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptors, IgG; Remission Induction; Trastuzumab; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Bevacizumab; Biomarkers, Pharmacological; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caveolin 1; Contraindications; Drug Therapy, Combination; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Stromal Cells; Survival Analysis | 2015 |
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.
Topics: Activation, Metabolic; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Esophageal Neoplasms; Fatigue; Female; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation; Young Adult | 2015 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Edema; Fatigue; Female; Follow-Up Studies; Health Status; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Tegafur | 2016 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Topics: Aged; Anemia; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Fatigue; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neutropenia; Paclitaxel; Pemetrexed; Predictive Value of Tests; Receptors, IgG | 2016 |
Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Fatigue; Female; Humans; Induction Chemotherapy; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Treatment Outcome | 2017 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diarrhea; Exanthema; Fatigue; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Pain; Skin Neoplasms; Survival Rate; Tumor Burden | 2009 |
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Young Adult | 2009 |
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2009 |
Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0
Topics: Aged; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Pyrimidines; Stomach Neoplasms; Tokyo; Treatment Outcome | 2009 |
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Humans; Hydrazines; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2009 |
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2010 |
Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Preoperative Care; Treatment Outcome | 2010 |
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Aminopeptidases; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fatigue; Female; Glycine; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel | 2010 |
Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Dose Fractionation, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Esophagitis; Esophagogastric Junction; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Paclitaxel; Polyglutamic Acid; Treatment Outcome | 2012 |
The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fatigue; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Quality of Life; Survival Rate | 2012 |
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Peptides; Treatment Outcome; Young Adult | 2012 |
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Micrometastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Thalidomide; Thromboembolism | 2012 |
Circadian rhythms, symptoms, physical functioning, and body mass index in breast cancer survivors.
Topics: Activities of Daily Living; Adult; Affective Symptoms; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Body Mass Index; Breast Neoplasms; Circadian Rhythm; Cyclophosphamide; Depression; Docetaxel; Doxorubicin; Fatigue; Female; Humans; Middle Aged; Paclitaxel; Quality of Life; Sleep; Survivors; Taxoids | 2012 |
Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fatigue; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Orchiectomy; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome | 2012 |
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fibroblast Growth Factor 2; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Suramin; Taxoids; Treatment Outcome | 2012 |
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Frail Elderly; Humans; Imatinib Mesylate; Lung; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Signal Transduction; Survival Analysis; Treatment Outcome | 2012 |
A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Fatigue; Female; Humans; Hypoalbuminemia; Hypokalemia; Hyponatremia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Estramustine; Etoposide; Fatigue; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Sepsis; Survival Analysis; Treatment Outcome | 2003 |
Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Blood; Breast Neoplasms; Cyclophosphamide; Cytokines; Data Interpretation, Statistical; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Interleukin-1; Interleukin-10; Interleukin-12; Interleukin-6; Interleukin-8; Middle Aged; Nausea; Paclitaxel; Pain; Patient Selection; Quality of Life; Tumor Necrosis Factor-alpha | 2004 |
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Heart Arrest; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperidines; Pyridines; Treatment Outcome | 2004 |
Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diarrhea; Esophageal Neoplasms; Fatigue; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2005 |
Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Fatigue; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
[Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arthralgia; Blood Cell Count; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2006 |
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Diarrhea; Drug Administration Schedule; Epirubicin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2006 |
[Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Fatigue; Female; Humans; Injections, Subcutaneous; Interleukin-11; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Platelet Count; Recombinant Proteins; Stomach Neoplasms; Thrombocytopenia; Treatment Outcome | 2006 |
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
[Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fatigue; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Radiotherapy; Radiotherapy, High-Energy; Survival Analysis | 2007 |
Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Hematologic Diseases; Hormones; Humans; Male; Nausea; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 1995 |
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Survival Rate; Thrombocytopenia | 1995 |
Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatigue; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Mucous Membrane; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel | 1997 |
Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estramustine; Fatigue; Female; Humans; Middle Aged; Nausea; Ovarian Neoplasms; Paclitaxel; Treatment Outcome; Vomiting | 1997 |
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan | 1999 |
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Nausea; Paclitaxel; Radiation-Protective Agents; Treatment Outcome; Vomiting | 1999 |
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Aspartate Aminotransferases; Breast Neoplasms; Diarrhea; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Taxoids; Time Factors | 2000 |
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Quinolines; Stomatitis; Taxoids; Vomiting | 2000 |
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasms; Paclitaxel; Tegafur; Uracil | 2000 |
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Constipation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2001 |
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Fatigue; Female; Fluorouracil; Glutathione; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leucovorin; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Thrombocytopenia; Treatment Outcome | 2001 |
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Nausea; Nervous System Diseases; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
21 other study(ies) available for paclitaxel and Lassitude
| Article | Year |
|---|---|
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy-Related Cognitive Impairment; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fatigue; Female; Humans; Long Term Adverse Effects; Longitudinal Studies; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Sleep Initiation and Maintenance Disorders | 2022 |
Antibiotic treatment inhibits paclitaxel chemotherapy-induced activity deficits in female mice.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Cognitive Dysfunction; Drug-Related Side Effects and Adverse Reactions; Fatigue; Female; Mice; Paclitaxel | 2023 |
Voluntary wheel running ameliorates select paclitaxel chemotherapy-induced sickness behaviors and associated melanocortin signaling.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Cachexia; Cytokines; Fatigue; Female; Fever; Ghrelin; Illness Behavior; Inflammation; Leptin; Melanocortins; Mice, Inbred C57BL; Motor Activity; Paclitaxel; Physical Conditioning, Animal; Signal Transduction | 2021 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases; Docetaxel; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Nail Diseases; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tunisia | 2021 |
Machine Learning Methods to Extract Documentation of Breast Cancer Symptoms From Electronic Health Records.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Electronic Health Records; Fatigue; Female; Humans; Machine Learning; Male; Middle Aged; Nausea; Paclitaxel; Pain | 2018 |
Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2018 |
Investigation of the relationship among fatigue, self-efficacy and quality of life during chemotherapy in patients with breast, lung or gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Quality of Life; Self Care; Self Efficacy; Surveys and Questionnaires; Turkey | 2019 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community Health Planning; Deoxycytidine; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Saskatchewan | 2019 |
First line therapy for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fatigue; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer.
Topics: Adult; Affect; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Cohort Studies; Computers, Handheld; Cyclophosphamide; Data Collection; Depression; Docetaxel; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Sleep; Taxoids | 2014 |
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Esophagogastric Junction; Fatigue; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab | 2014 |
Bu-zhong-yi-qi pill alleviate the chemotherapy-related fatigue in 4 T1 murine breast cancer model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Disease Models, Animal; Drugs, Chinese Herbal; Fatigue; Female; Humans; Magnoliopsida; Malondialdehyde; Mice; Paclitaxel; Phytotherapy; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2014 |
The inferior vena cava (IVC) syndrome as the initial manifestation of newly diagnosed gastric adenocarcinoma: a case report.
Topics: Adenocarcinoma; Anemia, Iron-Deficiency; Antineoplastic Combined Chemotherapy Protocols; Budd-Chiari Syndrome; Disease Progression; Edema; Endoscopy, Gastrointestinal; Fatigue; Female; Humans; Lower Extremity; Malaysia; Middle Aged; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Syndrome; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome; Vena Cava, Inferior | 2015 |
[Effect of Cancer Symptoms and Fatigue on Chemotherapy-related Cognitive Impairment and Depression in People with Gastrointestinal Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Anxiety; Camptothecin; Cognitive Dysfunction; Depression; Drug Therapy, Combination; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Hemoglobins; Humans; Irinotecan; Male; Memory; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Surveys and Questionnaires; Translating | 2016 |
Dramatic Response to Carboplatin, Paclitaxel, and Radiation in a Patient With Malignant Myoepithelioma of the Breast.
Topics: Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carboplatin; Dose Fractionation, Radiation; Fatigue; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Myoepithelioma; Paclitaxel; Radiotherapy, Adjuvant; Rare Diseases; Tomography, X-Ray Computed; Treatment Outcome; Weight Loss | 2016 |
Development of a mouse model for assessing fatigue during chemotherapy.
Topics: Animals; Circadian Rhythm; Drug-Related Side Effects and Adverse Reactions; Fatigue; Female; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Models, Animal; Nanoparticles; Neoplasms; Neurologic Examination; Paclitaxel; Sleep | 2011 |
The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy.
Topics: Actigraphy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Longitudinal Studies; Middle Aged; Paclitaxel; Prospective Studies; Sleep; Sleep Wake Disorders; Taxoids | 2012 |
Chemotherapy-induced neuropathic pain and its relation to cluster symptoms in breast cancer patients treated with paclitaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cluster Analysis; Depression; Fatigue; Female; Humans; Middle Aged; Neuralgia; Paclitaxel; Pain Measurement; Severity of Illness Index; Sleep Wake Disorders | 2013 |
Type-D personality exerts a stable, adverse effect on vital exhaustion in PCI patients treated with paclitaxel-eluting stents.
Topics: Age Factors; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Personality Inventory; Risk Factors; Sex Factors; Stents | 2007 |
Fatigue, depressive symptoms, and hopelessness as predictors of adverse clinical events following percutaneous coronary intervention with paclitaxel-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Coronary Disease; Depression; Fatigue; Female; Humans; Male; Middle Aged; Motivation; Myocardial Infarction; Paclitaxel; Prognosis; Proportional Hazards Models; Risk Factors; Stents; Survival Rate | 2007 |
Carcinoma of unknown primary site.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasms, Unknown Primary; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2000 |